I mean, I guess what I'm getting into here is that whereas today we keep seeing the effects, whether it's the liver, the kidney, the heart, obesity, and people with diabetes
Markets are now watching pricing, insurance coverage, and patient adoption as the next determinants of how disruptive this shift from injections to pills could be
View on PubMed Involvement of the AT1 Receptor in Effects of Angiotensin IV and LVV-Haemorphin 7 on Hippocampal Memory Demonstrated that angiotensin IV analogs (the parent class of Dihexa) improve hippocampal memory performance in rodents, supporting the AT4/IRAP receptor pathway as a target for cognitive enhancement (J Neurochem, 2010)
The impact of semaglutide on cardiovascular health has become a focal point of interest for clinicians and researchers alike, given the high prevalence of cardiovascular disease (CVD) among patients with type 2 diabetes and obesity
These approaches work well when speed matters and when there is defined endpoint for treatment